EMA Authorised: Wegovy (semaglutide) — Novo Nordisk A/S

View source ↗

Summary

EMA authorises Wegovy (semaglutide) by Novo Nordisk A/S for obesity and overweight.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

Status: Authorised. Therapeutic area: Obesity;Overweight. MAH: Novo Nordisk A/S. Decision date: 14/07/2026